Oncology ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o... For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?
Oncology ASCO 2026: Powerful evidence for the microbiome in oncology,... Can the state of someone’s gut microbiome – the balance of good and bad bacteria in their digestive tract – affect their response to cancer immunother
Oncology ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B... Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.
Oncology ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C... At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum about the company's ASCO data and broader oncology strategy.
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Oncology ASCO 26: Precision medicine takes a village, with Carolyn So... In this interview with pharmaphorum, J&J's Henar Hevia and Carolyn Sousa, share their some of the company's data wins at the show and talk trends.
Oncology ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o... For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.